|1.||Stetler-Stevenson, William G: 13 articles (11/2014 - 07/2004)|
|2.||Turpeenniemi-Hujanen, Taina: 13 articles (01/2013 - 01/2004)|
|3.||Tanus-Santos, Jose E: 7 articles (01/2015 - 07/2008)|
|4.||Yang, Shun-Fa: 7 articles (09/2013 - 07/2002)|
|5.||Mroczko, Barbara: 6 articles (04/2014 - 07/2010)|
|6.||Szmitkowski, Maciej: 6 articles (04/2014 - 07/2010)|
|7.||Wei, Beiyang: 6 articles (01/2013 - 12/2004)|
|8.||Jaworski, Diane M: 6 articles (04/2011 - 05/2005)|
|9.||Jensen-Taubman, Sandra: 5 articles (01/2014 - 11/2011)|
|10.||Bourboulia, Dimitra: 5 articles (01/2014 - 11/2011)|
03/20/2000 - "In human breast cancers, however, we show that high levels of TIMP-2 correlate with both shortened disease-free interval and overall survival. "
12/01/2006 - "In this study, we demonstrate that expression of TIMP-2 enhanced the antitumor efficacy of a replicating adenovirus in vivo, by reducing both tumor growth and angiogenesis."
03/01/2014 - "MMP-9 and TIMP-2 can affect the progression of cancer, which is valuable for studies on oral and maxillofacial SCC genes."
01/01/2014 - "Studies have shown that TIMP-2 has two roles in tumor invasion. "
01/01/2013 - "Overall, the present study demonstrated a lack of association between MMP-2 and TIMP-2 gene polymorphisms and cervical cancer susceptibility in women of Northern India. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
08/01/2013 - "These results suggest that faster progression of liver fibrosis could be associated with TIMP-2 -418 G homozygotes. "
05/01/2010 - "The results suggested that TIMP-2 ASON could prevent the progression of liver fibrosis in this rat model. "
05/01/2010 - "To interfere with this potentially effective target, we designed and synthesized two different ASON targeting TIMP-2, then mixed and transfected them by hydrodynamic injection into the rat livers with immune-induced liver fibrosis. "
05/01/2010 - "Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis."
03/01/2007 - "Knock-down of TIMP-2 expression attenuates CCl4-induced liver fibrosis and is a potential pharmacological target for gene therapy in liver fibrosis."
05/01/2002 - "Similarly, the MMP-2 to TIMP-2 ratio also showed statistically significant difference between normal bladder tissue and bladder carcinoma (P < 0.01). "
08/01/2013 - "The present study investigates the influence of MMP-1, MMP-9 and TIMP-2 on different clinicopathologic variables and disease-free survival (DFS) of patients with prostate carcinoma. "
01/01/2002 - "Immunohistochemical studies revealed a diffuse granular distribution of MMP-2, MMP-9, and TIMP-2 in the cytoplasm of the carcinoma cells. "
06/11/1997 - "This study determined whether transcription of matrix metalloproteinase (MMP)-9 and MMP-2, or tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2, or human papillomavirus (HPV) open reading frames (ORFs) is associated with invasive behavior in cervical carcinoma cells. "
02/01/1996 - "This study demonstrates cell surface binding of a synthetic MMP-2 inhibitor and provides new evidence of MMP-2 and TIMP-2 immunoreactivity in ovarian carcinomas and cell lines."
06/01/2015 - "These data demonstrated that heat stress could reduce intramuscular fibrosis, at least in part, through decreasing TGF-β1 and TIMP-2 protein expressions of tenotomised soleus muscle. "
02/01/2015 - "While progressing of pancreatic fibrosis the MMP-9 activity and the TIMP-2 level have lowered in comparison with these indices while its absence. "
08/15/2012 - "HYP and TIMP-2 levels were significantly correlated with periductal fibrosis status evaluated by ultrasonography. "
07/01/2012 - "The improvement of liver function and the regression of hepatic fibrosis were demonstrated by the parameters of a liver test and a histopathological assay, owing to the downregulated expression of COL-I, α-SMA, TIMP-2 and upregulated MMP-2. "
01/01/2012 - "Areas under the receiver operating characteristic curves of serum TIMP-2 and MMP-2 for predicting clinically significant fibrosis (stage F2 - F4) were 0.899 and 0.770, respectively. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
08/01/2009 - "Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma."
06/01/2004 - "Serum MMP-2 and TIMP-2 concentrations in patients with thyroid cancer did not significantly correlate with the clinical staging of thyroid cancer."
06/01/2004 - "MMP-2 and its tissue inhibitor TIMP-2 apparently play a significant role in the pathogenesis of thyroid cancer. "
06/01/2004 - "The aim of the study was to evaluate the concentration of MMP-2 and TIMP-2 in blood serum of patients with benign and malignant thyroid tumours and the effect of surgical treatment on these parameters in the postoperative period as well as assessment whether to MMP-2 and TIMP-2 serum concentration in patients with thyroid cancer positively correlates with the clinical staging classification of the International Union Against Cancer (UICC). "
08/01/2008 - "Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications."
|1.||Tissue Inhibitor of Metalloproteinase-1
|2.||Tissue Inhibitor of Metalloproteinases (TIMP)
|3.||Messenger RNA (mRNA)
|4.||Matrix Metalloproteinase 2 (Gelatinase A)
|5.||Matrix Metalloproteinase 14 (MT1-MMP)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Collagen Type I (Type I Collagen)
|9.||Matrix Metalloproteinase 9 (Gelatinase B)
|10.||Proteins (Proteins, Gene)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Breast Implants (Breast Implant)